| Clinical data | |
|---|---|
| Other names | RGFP-963 |
| Drug class | Histone deacetylase inhibitor; HDAC1, HDAC2, and HDAC3 inhibitor; Cognitive enhancer |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H20N4O |
| Molar mass | 344.418 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| Enzyme | IC50 (nM) |
|---|---|
| HDAC1 | 1,510 |
| HDAC2 | 750 |
| HDAC3 | 96 |
| HDAC4 | >20,000 |
| HDAC5 | >20,000 |
| HDAC6 | >20,000 |
| HDAC7 | >20,000 |
| HDAC8 | >20,000 |
| HDAC9 | >20,000 |
| HDAC10 | 6,640–10,000 |
| HDAC11 | 27,700 |
| Refs: [1][2] | |
RGFP963, or RGFP-963, is a histone deacetylase (HDAC) inhibitor which is used in scientific research.[1][2][3][4][5] It is a selective class I HDAC inhibitor, including of HDAC1, HDAC2, and HDAC3 (IC50 = 1,510 nM, 750 nM, and 96 nM, respectively).[1][2] The drug also weakly inhibits HDAC10 (IC50 = 6,640–10,000 nM), whereas it showed no inhibition of other HDACs at a concentration of up to 20,000 nM.[1][2] RGFP963 enhances the consolidation of cued fear extinction in rodents, with this thought to be mediated by inhibition of HDAC1 and/or HDAC2 and not by inhibition of HDAC3.[1][4] In addition, the drug promotes synaptogenesis in vitro and enhances memory in an animal model of Alzheimer's disease in rodents.[2][4][6] It also enhanced cognition in a model of amyotrophic lateral sclerosis (ALS) in rodents.[3] The pharmacokinetics of RGFP963 have been studied and it is brain-penetrant in rodents.[1] RGFP963 was first described in the scientific literature by 2015.[1][2]
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.